452365-99-0

Basic information

• Product Name: N-(3-bromophenyl)cyclohexanecarboxamide
• Synonyms: N-(3-bromophenyl)cyclohexanecarboxamide
• CAS NO: 452365-99-0
• Molecular Formula: C₁₃H₁₆BrNO
• Molecular Weight: 282.19
• Mol File: 452365-99-0.mol

Chemical Properties

• Boiling Point: 425.7±28.0 °C(Predicted)
• Appearance: /
• Density: 1.402±0.06 g/cm3(Predicted)
• PKA: 14.33±0.70(Predicted)
• CAS DataBase Reference: N-(3-bromophenyl)cyclohexanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromophenyl)cyclohexanecarboxamide(452365-99-0)
• EPA Substance Registry System: N-(3-bromophenyl)cyclohexanecarboxamide(452365-99-0)

Safety Data

• Hazardous Substances Data: 452365-99-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-(3-bromophenyl)cyclohexanecarboxamide is utilized as a building block in the synthesis of various pharmaceutical compounds and agrochemicals. Its unique structure allows for the creation of a wide range of molecules with different biological activities.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N-(3-bromophenyl)cyclohexanecarboxamide is employed as a key intermediate for the development of new drugs. Its potential biological activity makes it a valuable candidate for research and drug discovery processes.
Used in Pharmaceutical Industry:
N-(3-bromophenyl)cyclohexanecarboxamide is used as a precursor in the production of pharmaceuticals. Its versatility in chemical reactions enables the synthesis of diverse drug molecules with therapeutic potential.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, N-(3-bromophenyl)cyclohexanecarboxamide serves as a starting material for the synthesis of various agrochemicals, such as pesticides and herbicides, contributing to the development of effective solutions for agricultural challenges.
Overall, N-(3-bromophenyl)cyclohexanecarboxamide's diverse applications in the chemical and pharmaceutical industries highlight its importance as a versatile compound with significant potential in the development of new molecules for various purposes.

Upstream product

• 591-19-5 m-Bromoaniline 
• 2719-27-9 cyclohexanylcarbonyl chloride 

Downstream Products

• 592524-75-9 fexaramate 

Relevant articles and documents

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

Provided are compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

NON-STEROIDAL FXR AGONISTS

ABSTRACT Potent non-steroidal farnesoid X receptor (FXR) agonists are N-aryl-N-arylmethyl amido and ureido compounds having the chemical structure represented by the following formula (I): INSERT FORMULA wherein E1 is (C1-C8)alkyl, cyclohexyl, 2-furyl, 3-

Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.

The efficient regulation of cholesterol biosynthesis, metabolism, acquisition, and transport is an essential component of lipid homeostasis. The farnesoid X receptor (FXR) is a transcriptional sensor for bile acids, the primary product of cholesterol metabolism. Accordingly, the development of potent, selective, small molecule agonists, partial agonists, and antagonists of FXR would be an important step in further deconvoluting FXR physiology. Herein, we describe the development of four novel classes of potent FXR activators originating from natural product-like libraries. Initial screening of a 10,000-membered, diversity-orientated library of benzopyran containing small molecules for FXR activation utilizing a cell-based reporter assay led to the identification of several lead compounds possessing low micromolar activity (EC50's = 5-10 microM). These compounds were systematically optimized employing parallel solution-phase synthesis and solid-phase synthesis to provide four classes of compounds that potently activate FXR. Two series of compounds, bearing stilbene or biaryl moieties, contain members that are the most potent FXR agonists reported to date in cell-based assays. These compounds may find future utility as chemical tools in studies aimed at further defining the physiological role of FXR and discovering potential therapeutic agents for the treatment of diseases linked to cholesterol and bile acid metabolism and homeostasis.